Articles tagged with Neutralizing Antibodies
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Scientists at Scripps Research have determined the structure of the critical protein complex that lets Lassa virus infect human cells, identifying new antibodies and vaccine targets. The research also found a high level of conservation across different lineages of the virus, paving the way for more effective vaccines and treatments.
The study, published in Science Translational Medicine, shows robust T-cell responses in volunteers participating in a phase 1 clinical trial of a self-assembling nanoparticle HIV vaccine. The antigen used stimulates VRC01-class B cells, an immune response considered promising for boosting in further studies.
MIT chemists develop rapid test to determine whether individuals have neutralizing antibodies against Covid-19, offering protection against future infections. The technique uses a fingerprint of sugar molecules to identify neutralizing antibodies in blood samples.
The study found that vaccine type significantly impacts the immune response to COVID-19, with Pfizer and Moderna offering a stronger antibody response than Johnson & Johnson. Age, sex, BMI, and smoking status also affect vaccine effectiveness, with smokers experiencing a 240% lower response.
Researchers discovered a 'cocktail' of human antibodies that show promise in fighting severe SARS-CoV-2 infections, including Omicron variants. The study revealed how the original Moderna vaccine could prompt the body to produce these broad-spectrum antibodies.
A new study creates an experimental combo vaccine by adding a key protein from norovirus to a harmless strain of rotavirus, generating antibodies against both viruses. Mice produced neutralizing antibodies in response to the vaccine.
New research from Washington University School of Medicine reveals that updated booster shots targeting specific COVID-19 variants can elicit a broad antibody response capable of neutralizing new variants. Periodic boosters may be necessary to maintain population immunity as the virus continues to evolve.
Researchers at La Jolla Institute for Immunology have developed a high-resolution view of the LCMV glycoprotein, revealing its structure and potential vulnerabilities. The breakthrough enables the development of an engineered antibody that can prevent LCMV disease, offering a new route to treatment.
A study published in Nature Immunology found that antibodies from previously infected patients can neutralize variants of the COVID-19 disease, including the Omicron variant. These broadly neutralizing antibodies have unique biochemical and structural features that enable them to block the virus from entering human cells.
A research team from MedUni Vienna found that only neutralizing antibodies can inform us about protection against new infections. The study discovered a previously unknown weak point of the virus, which is a conserved site on the surface of the virus.
Researchers developed a new prototype treatment using a human antibody that neutralizes neurotoxins from African and Asian elapid snakes, with potential for broader cross-reactivity. The treatment showed promising results in preventing death from venom envenoming in mice.
Researchers at Osaka University found that male patients with COVID-19 have a faster loss of circulating Treg cells, leading to dysregulated antibody responses. Females, on the other hand, have higher levels of these cells, which may help protect them from infection.
Scientists have identified a new class of 'bivalent' antibodies that can bind to two viral targets at once, neutralizing multiple Omicron variants. These potent antibodies retain efficacy against early SARS-CoV-2 variants and several later Omicron sub-lineages.
Researchers from Kanazawa University have developed a nanoscopic tool using high-speed atomic force microscopy to assess alternative COVID-19 prevention methods. They found that viral surface roughness can enhance the infectivity of SARS-CoV-2 variants, but spike-neutralizing antibodies neutralize the Delta variant spike protein.
Research finds that individuals who received monoclonal antibodies before COVID vaccination exhibit a diverse antibody response, increasing the coverage provided by vaccines. This phenomenon, known as antibody feedback inhibition, is beneficial for diversifying immune responses to viruses.
Researchers at Scripps Research, IAVI, Fred Hutch, and VRC publish study data in Science, revealing a stepwise approach to producing antibodies capable of targeting wide range of HIV variants. The Phase 1 trial shows favorable safety profile and induces targeted response in 97% of vaccinated individuals.
Researchers found that antibodies against one of the two main domains of the SARS-CoV-2 viral entry machinery elicit a broad antibody response against many variants. This suggests strategies for clinical development of variant-resistant vaccines.
A recent study found that the Omicron sub-lineage BQ.1.1 is resistant to all approved antibody therapies, posing a risk to high-risk patients. The researchers emphasize the importance of developing new antibody therapies specifically targeted at currently circulating and future viral variants.
Three circulating omicron subvariants have shown improved resistance to vaccine- and infection-generated neutralizing antibodies. BQ.1 and BQ.1.1 are dominating US infections, while BA.2.75.2 is the best at evading neutralizing antibodies.
Recent scientific studies have shed light on the effects of exposure to earlier SARS-CoV-2 forms on immune response to Omicron variants. Researchers identified a pan-variant antibody with ultra-potent neutralizing potency, which may help reduce treatment resistance.
Researchers at La Jolla Institute for Immunology have developed a new therapy for Lassa fever using a trio of rare human antibodies that can block viral infection. The therapy, called Arevirumab-3, was tested in non-human primates and proved 100% effective in treating the disease.
A study reveals that BA.2.75.2, a new Omicron sublineage, largely evades neutralizing antibodies and is resistant to several monoclonal antibody treatments, posing an increased risk of SARS-CoV-2 infections this winter.
A novel COVID-19 vaccine developed by Brazilian scientists combines two SARS-CoV-2 proteins to trigger a cellular immune response. The vaccine, called SpiN, showed promise in animal trials, protecting against three strains of the virus and reducing viral load by up to 50 times.
Researchers develop custom vaccines that induce broadly neutralizing antibodies to protect against HIV variants. The team uses a modified HIV spike protein to prime the immune system, paving the way for an effective HIV vaccine.
Researchers developed a faster, more affordable method to analyze serological data and predict COVID-19 wave behavior. The study showed that vaccination boosted immunity, with hybrid immunity producing higher protection levels. Antibody levels rose quickly after the first dose, especially in cities where case numbers were highest.
Researchers found that a 'slow delivery, escalating dose' vaccination strategy can prompt B cells to spend months mutating and evolving their antibodies, leading to more effective long-lasting vaccines. This breakthrough has implications for vaccines against pathogens like influenza, malaria, and SARS-CoV-2.
A team of scientists from SMART and NTU Singapore has developed a rapid point-of-care test kit that measures antibodies against SARS-COV-2 and its variants, offering personalized vaccination strategies. The test kit requires just 10 minutes to show results and has up to 93% accuracy.
Researchers at Duke University have identified a previously unknown barrier that separates the bloodstream from smelling cells in the upper airway of mice, which may hinder the effectiveness of vaccines. The BOB barrier also allows antibody-secreting plasma cells to produce neutralizing antibodies locally.
A team of scientists from SMART and NTU Singapore has developed a quick test kit that can determine a person's immunity against COVID-19 and its variants based on antibodies detected in a blood sample. The test kit, which requires just 10 minutes to show results, can be easily adapted for new variants of concern and other diseases.
A study found that neutralizing antibody levels against COVID-19 decline by at least 15% per month after a single booster shot, but can be restored with a second dose. Researchers tested serum from vaccinated adults and found a higher rate of decline in neutralizing antibodies against the BA.5 omicron variant.
Researchers assessed neutralizing antibody levels in children up to 16 months post-infection, finding varying immunity levels across age groups. The study's findings suggest a need for personalized vaccination strategies for this vulnerable population.
A large cross-sectional study found that baseline plasma antigen levels are highly associated with both the severity of pulmonary illness and clinically important patient outcomes in hospitalized COVID-19 patients. Higher antigen levels were linked to increased risk of pulmonary worsening and delayed hospital discharge.
Researchers at UBC have discovered a key vulnerability across all major COVID-19 variants that can be targeted by neutralizing antibodies. The 'master key' identified is the antibody fragment V H Ab6, which effectively neutralizes SARS-CoV-2 by attaching to the epitope on the spike protein.
Researchers developed a broadly neutralizing antibody that neutralized all currently known SARS-CoV-2 variants, including Omicron strains. The antibody works differently from existing antibodies and prevents the virus from fusing with host cells.
Scientists at Scripps Research have identified antibodies that induce broad immunity against SARS viruses, including emerging variants. The discovery reveals the antibody structures that produce this more comprehensive immune response and could inform the development of next-generation vaccines.
Researchers create a modified live attenuated mumps virus for delivery, showing it induces stronger immune responses and provides superior protection against SARS-CoV-2. The new vaccine candidate uses a prefusion version of the spike protein and offers potential to enhance MMR childhood vaccine.
A new study suggests that current vaccine boosters intensify protections against serious infection caused by Omicron subvariants. The research found that booster doses bring neutralizing antibodies to appreciable levels against all Omicron subvariants, consistent with other evidence of expanded memory B cells and antibody production.
A new clinical trial found that COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant, but these antibody levels decrease substantially within 3 months. The immune response to Omicron sub-lineages shows reduced susceptibility to rapidly emerging variants.
Researchers analyze delta variant's biophysical characteristics, revealing unique traits that evade neutralizing antibodies and contribute to severe symptoms. The study sheds light on why vaccinated individuals can still contract the virus and why delta variant hospitalizations are higher than other variants.
Researchers at Beth Israel Deaconess Medical Center found that newer Omicron subvariants BA.4 and BA.5 escape neutralizing antibodies induced by both vaccination and previous infection. These variants are now responsible for over 21% of new cases in the US, highlighting a shift in the COVID-19 landscape.
Scientists at Institut Pasteur developed potent neutralizing antibodies from convalescent COVID-19 individuals effective against various SARS-CoV-2 variants. These human antibodies are promising candidates for immunotherapies to prevent severe forms and/or treat COVID-19 in immunocompromised patients.
Researchers have identified two broadly neutralizing antibodies that can effectively neutralize all SARS-CoV-2 variants, including Omicron BA.1 and BA.2 subtypes. The antibodies, Cv2.1169 and Cv2.3194, were found to be fully active against Alpha, Beta, Gamma, and Delta variants.
A new study by the University of Colorado Anschutz Medical Campus explores the effects of multiple mutations in SARS-CoV-2 variants. The findings suggest that certain mutations work together to improve virus fitness, making it challenging for antibody treatments to neutralize new variants.
A new study published in Cell compares the four types of COVID-19 vaccines and reveals that most people retain some immune response to SARS-CoV-2. The researchers found that immune memory may not prevent infection but helps fight severe disease.
Children previously infected with COVID-19 or MIS-C are not protected against the newer Omicron variant. However, vaccination shows protective effects, according to a study published in Nature Communications.
Two studies found that a third dose of mRNA vaccine generates high enough antibody levels to neutralize BA.2 and deltacron, as well as other omicron sublineage variants. Booster shots show stronger protection against these variants than just two doses, particularly against deltacron.
Researchers found that a single mRNA vaccine booster shot can provide the same level of protection as three doses, making it a promising investment for resource-poor countries. The study suggests that this strategy could benefit billions of people worldwide and help combat emerging COVID-19 variants.
A study found that vaccines induce immune responses beyond neutralizing antibodies, involving T cells and the Fc receptor, to control viral replication and prevent severe disease. The researchers observed dose-dependent effects on these immune mechanisms, providing insights for future vaccine design and boosting.
Researchers at George Mason University developed Ha-CoV-2, a non-replicating rapid SARS-CoV-2 pseudovirus system to measure antibody blocking efficacy. The technology can rapidly assess neutralizing antibodies and has significant impacts for pandemic control strategies.
New research suggests that ADCC responses and strain susceptibility influence HIV-1 mother-to-child transmission during breastfeeding. Enhancing ADCC through a vaccine may not be sufficient to prevent transmission due to chronically infected individuals' ADCC-resistant strains.
Researchers found that people who had COVID-19 and then got vaccinated generated an immune response more specific to fighting viral infections, producing a broader antibody response. This hybrid immunity also produced a cellular immune response called Th1 response, which is antiviral.
A booster dose of the Pfizer/BioNTech vaccine significantly increases antibodies against SARS-CoV-2, reversing a drop in immunity after two doses. In subjects given CoronaVac or Oxford-AstraZeneca vaccines, the booster raised immunity by a factor of 25 and 7, respectively.
A study found that double vaccinated individuals generate a potent and broad neutralizing antibody response after a delta breakthrough infection. This response provides protection against current variants of concern, including omicron.
The investigational vaccine targets both the spike and nucleocapsid proteins, producing neutralizing antibodies and inducing T cell responses against SARS-CoV-2. COH04S1 is being studied in Phase 2 trials for immunocompromised patients and as a booster for healthy adult volunteers.
Researchers found that two-dose mRNA vaccines against the original and early variants of the SARS-CoV-2 virus offer little to no protection against the omicron variant. A third COVID-19 mRNA vaccine booster shot, however, enhances immune response and provides comparable protection to the delta variant.
A recent study found that individuals vaccinated three times or those who were vaccinated after an earlier COVID-19 infection had comparable neutralizing antibody activity to those with a breakthrough case. The study suggests that repeated exposure to SARS-CoV-2 antigens enhances the quality of antibody responses.
Researchers are working tirelessly to develop vaccines against the Omicron variant, a crucial step in combating the pandemic. By understanding the biology of Omicron, scientists hope to create effective treatments and boosters to protect against future pandemics.
A study found an antibody, P36-5D2, to decrease infectious virus load in lungs and brain, reducing lung disease in laboratory models. The discovery offers hope for developing antibody therapies against COVID-19 and its emerging variants.
A new study reveals that SARS-CoV-2 limits viral particle release and instead spreads through cell-to-cell transmission, enabling efficient infection without the need for antibodies. This stealthy transmission method makes it challenging for the host immune system to target and neutralize the virus.
Scientists have developed a fusion protein that successfully blocks replication of SARS-CoV-2 and related viruses in cell culture tests. The protein combines ACE2 with human antibody fragments, providing reliable protection against future mutations.